On October 24th, the listed company Jincheng Pharm (SZ300233) released its financial report for the third quarter of 2023. The company's operating income for the third quarter reached 863 million yuan, representing a year-on-year increase of 16.77%. However, its net profit declined by 21.95% to 30.77 million yuan, and the non-GAAP net profit also dropped by 21.17% to 26.72 million yuan.
According to a report, Jincheng Pharm achieved a total operating revenue of 2.569 billion yuan in the first three quarters of 2023, representing a year-on-year decrease of 0.87%. The net profit reached 132 million yuan, experiencing a significant decline of 48.73% compared to the same period last year. The adjusted net profit, excluding non-recurring items, stood at 119 million yuan, reflecting a 52.81% year-on-year decrease. The basic earnings per share amounted to 0.34 yuan.
According to the report, Jincheng Pharm Chemical Co., Ltd., a wholly-owned subsidiary of the company, received a "Tobacco Monopoly Production Enterprise License" (e-cigarette nicotine production) issued by the National Tobacco Monopoly Administration in July 2023.
It has been stated that the newly acquired "Tobacco Monopoly Production Enterprise License" has made changes to the approved production scale, scope of permission, and validity period of the original certificate. The company is now permitted to engage in domestic and export business of e-cigarette nicotine in compliance with the law. The production scale will not exceed the data approved by the State Tobacco Monopoly Bureau, and the validity period has been extended until June 30, 2025.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
